KR-20260064610-A - Composition for preventing or treating inflammatory bowel disease comprising germinated oat extract

Abstract

The present invention relates to a composition for the prevention, improvement, or treatment of inflammatory bowel disease comprising a sprouted oat ( Avena sativa L. ) extract, wherein the composition improves intestinal permeability and improves tight junction integrity within an inflamed intestinal environment, and thus can be effectively used in the manufacture of pharmaceuticals, health functional foods, foods, or prebiotics for the prevention, improvement, or treatment of inflammatory bowel disease.

Inventors

• 피재호

Assignees

• 주식회사 아이엔지알

Dates

Publication Date

20260507

Application Date

20251029

Priority Date

20241030

Claims (17)

1. A pharmaceutical composition for the prevention or treatment of inflammatory bowel disease (IBD) comprising sprouted oat ( Avena sativa L. ) extract and a pharmaceutically acceptable carrier.
2. A pharmaceutical composition according to claim 1, wherein the inflammatory bowel disease is one or more selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), irritable bowel syndrome, intestinal Behcet's disease, indeterminate colitis, infectious enteritis, bacterial enteritis, viral enteritis, amoebic enteritis, hemorrhagic rectal ulcer, ischemic bowel disease, radiation enteritis, tuberculous enteritis, and leaky gut syndrome.
3. A pharmaceutical composition according to claim 1, wherein the germinated oats are obtained by germinating oat seeds for 1 to 3 days with a 2:1 light-dark cycle and then treating with an inducer for 2 to 5 days with a 2:1 light-dark cycle.
4. A pharmaceutical composition according to paragraph 3, wherein the inducer is abscisic acid, methyl jasmonate, or a combination thereof.
5. In claim 1, the germinated oat extract is 1) a step of extracting by adding an extraction solvent to germinated oats; and 2) Prepared by a method comprising the step of filtering, concentrating, or drying the extract of step 1), and Here, the extraction solvent of step 1) above is one or more solvents selected from the group consisting of water and organic solvents, and A pharmaceutical composition in which the drying of step 2) above is by spray drying.
6. A pharmaceutical composition according to claim 5, wherein the organic solvent is one or more selected from the group consisting of alcohols having 1 to 5 carbon atoms, ethyl acetate, acetone, ether, chloroform, benzene, hexane, and dichloromethane.
7. A pharmaceutical composition according to claim 1, wherein the germinated oat extract improves intestinal permeability and tight junction (TJ) integrity resulting from inflammatory bowel disease.
8. A pharmaceutical composition according to claim 1, characterized in that the germinated oat extract promotes the proliferation of beneficial bacteria in the intestines.
9. A pharmaceutical composition according to claim 8, characterized in that the beneficial bacteria are one or more lactic acid bacteria selected from the group consisting of Lactobacillus plantarum and Lactobacillus delbrueckii.
10. A health functional food composition for the prevention or improvement of inflammatory bowel disease (IBD) containing sprouted oat ( Avena sativa L. ) extract.
11. A health functional food composition according to claim 10, wherein the inflammatory bowel disease is one or more selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), irritable bowel syndrome, intestinal Behcet's disease, indeterminate colitis, infectious enteritis, bacterial enteritis, viral enteritis, amoebic enteritis, hemorrhagic rectal ulcer, ischemic bowel disease, radiation enteritis, tuberculous enteritis, and leaky gut syndrome.
12. A health functional food composition according to claim 10, wherein the germinated oat extract improves intestinal permeability and tight junction (TJ) integrity resulting from inflammatory bowel disease.
13. A health functional food composition according to claim 10, wherein the health functional food is one or more formulations selected from the group consisting of health functional food preparations such as tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, and bars, beverages, gums, and candies.
14. A food composition for preventing or improving inflammatory bowel disease (IBD) containing sprouted oat ( Avena sativa L. ) extract.
15. A food composition according to claim 14, wherein the inflammatory bowel disease is one or more selected from the group consisting of ulcerative colitis (UC), Crohn's disease (CD), irritable bowel syndrome, intestinal Behcet's disease, indeterminate colitis, infectious enteritis, bacterial enteritis, viral enteritis, amoebic enteritis, hemorrhagic rectal ulcer, ischemic bowel disease, radiation enteritis, tuberculous enteritis, and leaky gut syndrome.
16. A food composition according to claim 14, wherein the food is one or more selected from the group consisting of various drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, soup, beverages, alcoholic beverages, and vitamin complexes.
17. A prebiotic composition for improving intestinal flora containing sprouted oat ( Avena sativa L. ) extract as an active ingredient.

Description

Composition for preventing or treating inflammatory bowel disease comprising germinated oat extract The present invention relates to a composition for the prevention or treatment of inflammatory bowel disease comprising a sprouted oat extract with an increased avenanthramide content. Inflammatory bowel disease refers to chronic inflammatory diseases in which inflammation or ulcers develop in the intestines due to unknown causes, such as ulcerative colitis (UC), Crohn's disease (CD), and Behcet's disease. Inflammatory bowel disease is common worldwide and has recently shown a significantly increasing trend in Korea; however, the causes and mechanisms of the disease are relatively complex and are not yet precisely known. Drugs used to treat existing inflammatory bowel disease include steroidal immunosuppressants, 5-aminosalicylic acid (5-ASA) class drugs that block the production of prostaglandins (e.g., sulfasalazine, etc.), and mesalazine. Although anti-inflammatory drugs and immunosuppressants are prescribed as exemplified above, they have side effects such as nausea, vomiting, headache, hemolytic anemia, and male infertility. Furthermore, because there is a significant number of patients who do not respond to treatment or whose efficacy is reduced, there is a continuous demand for the development of safer and more effective treatments. Inflammatory bowel disease (IBD) is characterized by damage to the integrity of the epithelial barrier caused by inflammation. Damaged barrier integrity and increased permeability of epithelial tight junctions lead to barrier weakening, a condition known as the "leaky gut." Recent studies have revealed that the barrier is critical not only for IBD but also for various other diseases, including autoimmune diseases associated with barrier integrity. Maintaining and strengthening barrier integrity is essential for the prevention and treatment of IBD and various other diseases. Recently, natural bioactive substances known for their anti-inflammatory effects have garnered attention as important potential therapeutic agents for IBD. Oats ( Avena sativa L. ) contain abundant biologically active components, thereby exhibiting various health-promoting effects including antioxidant, anti-diabetic, antibacterial, anticancer, antihypertensive, immunomodulatory, antihyperlipidemia, anti-obesity, cardioprotective, and anti-inflammatory effects. According to prior research, sprouted oats are known to be effective against atopic dermatitis by regulating the expression of skin binding proteins, improving skin barrier function, and treating skin barrier disruption. Oats contain various phenolic compounds, among which avenanthramides (AVNs) are a type of phenolic alkaloid represented by the following chemical formula I and are specifically contained in oats, and the avenanthramide and phenolic compound content of germinated oats is much higher than that of ungerminated oat seeds. [Chemical Formula I] Avenanthramide is known as a powerful antioxidant with established effects including blood pressure regulation, inhibition of skin irritation, and anti-atherosclerosis. Recently, it has been revealed that it can also be used to treat hearing loss and neurodegenerative diseases. As such, research on the applications of avenanthramide is actively underway, and it is gaining attention as a useful component that can be used to treat various diseases. However, in the context of inflammatory bowel disease (IBD), the specific effects of the active ingredients of sprouted oats on intestinal permeability and tight junction (TJ) integrity have not been clearly established. Accordingly, the inventors adopted an integrated approach for initial in silico evaluation using the Combination-Oriented Natural Product Database with Unified Terminology (COCONUT), which combines bioinformatics analysis and chemical profiling, with inflammatory bowel disease (IBD) as a phenotype associated with the interaction between the bioactive compounds of germinated oats and the genetic and proteomic environment determining tight junction integrity. Furthermore, by focusing on efficacy evaluation through insilico prediction validated by an in vitro model using a Caco-2 cell model, the inventors elucidated the fundamental mechanism of the effect of germinated oats on intestinal permeability and confirmed that germinated oat extract (GOE) has an effect on inflammatory bowel disease by improving tight junction integrity within an inflamed intestinal environment, thereby completing the present invention. Figure 1 shows the qualitative chromatographic analysis of phenols and alkaloids in germinated oat extract, (A) positive mode; (B) negative mode. Figure 2 shows the results of a predictive analysis of potential target genes and biological pathways, comprising: (a) a network of complex gene phenotypes (inflammatory bowel disease) in germinated oats; (b) genes related to tight junctions (GO:CC); (c) protein-protein interaction (PPI) an